These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12173912)

  • 1. Relationship between serum vitamin d status and clinical manifestations of primary hyperparathyroidism.
    Bandeira F; Caldas G; Freese E; Griz L; Faria M; Bandeira C
    Endocr Pract; 2002; 8(4):266-70. PubMed ID: 12173912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D status in primary hyperparathyroidism in India.
    Harinarayan CV; Gupta N; Kochupillai N
    Clin Endocrinol (Oxf); 1995 Sep; 43(3):351-8. PubMed ID: 7586606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of 1,25(OH)2D production by hypercalcemia in osteitis fibrosa cystica: influence on parathyroid hormone secretion and hungry bone disease.
    Brossard JH; Garon J; Lepage R; Gascon-Barré M; D'Amour P
    Bone Miner; 1993 Oct; 23(1):15-26. PubMed ID: 8274876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marked direct suppression of primary hyperparathyroidism with osteitis fibrosa cystica by intravenous administration of 1,25-dihydroxycholecalciferol.
    Patron P; Gardin JP; Borensztein P; Prigent A; Paillard M
    Miner Electrolyte Metab; 1989; 15(6):321-5. PubMed ID: 2615719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovery pattern of patients with osteitis fibrosa cystica in primary hyperparathyroidism after successful parathyroidectomy.
    Agarwal G; Mishra SK; Kar DK; Singh AK; Arya V; Gupta SK; Mithal A
    Surgery; 2002 Dec; 132(6):1075-83; discussion 1083-5. PubMed ID: 12490858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of cortical osteoporosis in mild and severe primary hyperparathyroidism and its relationship with bone markers and vitamin D status.
    Bandeira F; Griz LH; Bandeira C; Pinho J; Lucena CS; Alencar C; Thé AC; Diniz ET
    J Clin Densitom; 2009; 12(2):195-9. PubMed ID: 19138544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteitis fibrosa cystica-a forgotten radiological feature of primary hyperparathyroidism.
    Misiorowski W; Czajka-Oraniec I; Kochman M; Zgliczyński W; Bilezikian JP
    Endocrine; 2017 Nov; 58(2):380-385. PubMed ID: 28900835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calciotropic hormones and bone markers in the elderly.
    Gallagher JC; Kinyamu HK; Fowler SE; Dawson-Hughes B; Dalsky GP; Sherman SS
    J Bone Miner Res; 1998 Mar; 13(3):475-82. PubMed ID: 9525348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial.
    Lips P; Duong T; Oleksik A; Black D; Cummings S; Cox D; Nickelsen T
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1212-21. PubMed ID: 11238511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D status in female patients with primary hyperparathyroidism: does it play a role in skeletal damage?
    Carnevale V; Manfredi G; Romagnoli E; De Geronimo S; Paglia F; Pepe J; Scillitani A; D'Erasmo E; Minisola S
    Clin Endocrinol (Oxf); 2004 Jan; 60(1):81-6. PubMed ID: 14678292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism.
    Kantorovich V; Gacad MA; Seeger LL; Adams JS
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3541-3. PubMed ID: 11061498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different responses of free and peptide-bound cross-links to vitamin D and calcium supplementation in elderly women with vitamin D insufficiency.
    Kamel S; Brazier M; Rogez JC; Vincent O; Maamer M; Desmet G; Sebert JL
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3717-21. PubMed ID: 8855828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum concentrations of 25-hydroxyvitamin D and its association with bone mineral density and serum parathyroid hormone levels during winter in urban males from Guiyang, Southwest China.
    Zhang Q; Shi L; Peng N; Xu S; Zhang M; Zhang S; Li H; Zhuang H; Gong M; Wu D; Wang R
    Br J Nutr; 2016 Mar; 115(6):960-6. PubMed ID: 26843386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrolithiasis and bone involvement in primary hyperparathyroidism.
    Silverberg SJ; Shane E; Jacobs TP; Siris ES; Gartenberg F; Seldin D; Clemens TL; Bilezikian JP
    Am J Med; 1990 Sep; 89(3):327-34. PubMed ID: 2393037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From mild to severe primary hyperparathyroidism: The Brazilian experience.
    Bandeira F; Griz L; Caldas G; Bandeira C; Freese E
    Arq Bras Endocrinol Metabol; 2006 Aug; 50(4):657-63. PubMed ID: 17117291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fractures and vertebral bone mineral density in patients with renal osteodystrophy.
    Piraino B; Chen T; Cooperstein L; Segre G; Puschett J
    Clin Nephrol; 1988 Aug; 30(2):57-62. PubMed ID: 3180516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classical complications of primary hyperparathyroidism.
    Minisola S; Gianotti L; Bhadada S; Silverberg SJ
    Best Pract Res Clin Endocrinol Metab; 2018 Dec; 32(6):791-803. PubMed ID: 30665547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D, parathyroid hormone, and bone mineral density status in kidney transplant recipients.
    Savaj S; Ghods FJ
    Iran J Kidney Dis; 2012 Jul; 6(4):295-9. PubMed ID: 22797100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large parathyroid adenomas: Potential mechanisms to reconcile adenoma size and disease phenotype.
    Bhan A; Athimulam S; Kumari P; Pal R; Bhadada SK; Cook BC; Qiu S; Rao SD
    Front Endocrinol (Lausanne); 2023; 14():1009516. PubMed ID: 36817587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.